BARE BONES content is posted to these pages in real time.
Monthly compilations are available in PDF form.
Vericel posted 3Q16 Carticel revenue of US $8.3MM, +7.8% vs. 3Q15, as reported. Carticel is an autologous chondrocyte implant marketed in the U.S. for the treatment of knee cartilage defects.
Sources: Vericel Corporation; ORTHOWORLD Inc.